Alzheimer’s Drug Discovery Foundation (ADDF): Accelerating Drug Discovery for Frontotemporal Degeneration

The Alzheimer’s Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) seek to accelerate and support innovative drug discovery for frontotemporal degeneration (FTD) and related dementias.

Priority areas for this program include:

  • Development and testing of novel high throughput screening assays;
  • Identification and in vitro testing of potentially disease modifying compounds or biologics, including medicinal chemistry refinement, ADME, toxicology, pharmacokinetics, and pharmacodynamics studies; and
  • Testing of novel lead compounds, biologics, or repurposed drug candidates in a relevant animal model for preclinical proof of concept.

 Funding & Duration

Grants are provided for 1 year, up to US $150,000 (approx AUD $197,400).


Applications may be submitted by non-profit academic institutions and for-profit biotechnology companies, both public and private, worldwide.

Submission Requirements & Due Dates

Further Information

Need Help?

This entry was posted in Engineering, Computer & Mathematical Sciences, Funding by Award Type, Grants (Project Funds), Health & Medical Sciences, International Funding, Proof of Concept, Market Testing, Commercialisation, Sciences. Bookmark the permalink.

Comments are closed.